Determination of lamotrigine unbound fraction using ultrafiltration and validated LC-MS method
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14310%2F24%3A00139973" target="_blank" >RIV/00216224:14310/24:00139973 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Determination of lamotrigine unbound fraction using ultrafiltration and validated LC-MS method
Original language description
Total plasma concentrations are commonly used for therapeutic drug monitoring of antiepileptic drugs (AED). On the other hand, drug activity and at least some of adverse effects depend on the unbound fraction of a drug in the bloodstream. The determination of free (unbound) concentrations by ultrafiltration is expected to reflect the effective drug concentration. Further, saliva is considered as a plasma ultrafiltrate, thus referring to free drug concentration. Therefore, the aim was to develop a method for the measurement of total and unbound AED concentrations in plasma and correlate them to saliva AED concentration. As a model drug, lamotrigine (LTG) was chosen since it is one of the most widely used AED and is moderately bound to albumin (~55%) [1]. Pilot data showed that the concentrations measured in plasma ultrafiltrate and saliva were in close proximity, even though total plasma concentrations are much higher and wildly differ between individual samples. More data must be available to determine the correlation between saliva and plasma concentrations and saliva and ultrafiltrate concentrations.
Czech name
—
Czech description
—
Classification
Type
O - Miscellaneous
CEP classification
—
OECD FORD branch
20602 - Medical laboratory technology (including laboratory samples analysis; diagnostic technologies) (Biomaterials to be 2.9 [physical characteristics of living material as related to medical implants, devices, sensors])
Result continuities
Project
<a href="/en/project/NU23-08-00229" target="_blank" >NU23-08-00229: Minimally invasive methods for the personalized pharmacotherapy of epilepsy</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů